Roche Diagnostics` Genome Sequencer 20 System Powers MWG Biotech AG/ Eurofins | Medigenomix Sequencing Service
News Nov 22, 2006
Roche Diagnostics has supplied the Genome Sequencer 20 system to Eurofins | Medigenomix / MWG Biotech.
Through the purchase of the GS 20 system, Eurofins | Medigenomix / MWG Biotech becomes the first international service provider in Germany to offer their customers access to the next generation of DNA sequencing technology via their production facility in Martinsried.
By combining the companies’ current sequencing platform, mainly based on Sanger method and the GS 20 technology, MWG and Medigenomix are able to sequence and compare bacterial genomes in only a couple of days.
MWG Biotech AG, Ebersberg, Germany, has a 10 year experience in worldwide DNA sequencing services. In August 2005, the company joined forces with Eurofins Medigenomix GmbH, Munich, a recognized provider of high quality molecular biology laboratory services.
“As the first sequencing provider in Germany using GS 20 in their own facilities, MWG Biotech AG / Eurofins | Medigenomix will benefit from the systems performance and from its versatility regarding applications, from whole genome sequencing to cancer research,” states Manfred Baier, Head of Roche Applied Science, a business area for Roche Diagnostics.
“They make fast sequencing useful for researchers who do not need the full capacity of an own GS 20 system or who do not have all expertise in house, thus further broadening the application field for the system.”
“Being part of the Eurofins Group family, MWG and Medigenomix have the financial capability to invest in state-of-the-art technologies, in order to offer unmatched services to our customers,” informs Bruno Poddevin, Chief Operating Officer, MWG Biotech AG.
And Brigitte Obermaier, Managing Director, Eurofins | Medigenomix, added: “Our agreement and excellent collaboration with Roche Diagnostics will enable a streamlined and smooth integration of the new technology into the existing process workflow.”
When a protein named "Merlin" fails to do its job, people can develop slow-growing, life-disrupting auditory nerve tumors that can disrupt their hearing and balance. Now scientists at Cincinnati Children's have discovered much more about how Merlin does its job – by working behind the scenes through a network of more than 50 other proteins.READ MORE